Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure

Piergiuseppe Agostoni, MD, PhD; Ugo Corrà, MD; Gaia Cattadori, MD; Fabrizio Veglia, PhD; Elisa Battaia, MD; Rocco La Gioia, MD; Angela B. Scardovi, MD; Michele Emdin, MD; Marco Metra, MD; Gianfranco Sinagra, MD; Giuseppe Limongelli, MD, PhD; Rosa Raimondo, MD; Federica Re, MD; Marco Guazzi, MD, PhD; Romualdo Belardinelli, MD; Gianfranco Parati, MD; Damiano Magri, MD, PhD; Cesare Fiorentini, MD; Mariantonietta Cicoira, MD, PhD; Elisabetta Salvioni, PhD; Marta Giovannardi, MSc; Alessandro Mezzani, MD; Domenico Scrutinio, MD; Andrea Di Lenarda, MD; Valentina Mantegazza, MD; Roberto Ricci, MD; Anna Apostolo, MD; AnnaMaria Iorio, MD; Stefania Paolillo, MD; Pietro Palermo, MD; Mauro Contini, MD; Corrado Vassanelli, MD, PhD; Claudio Passino, MD; Massimo F. Piepoli, MD, PhD; on behalf of the MECKI Score Research Group*

Background—In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified. We evaluated whether this finding has a prognostic meaning.

Methods and Results—We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment. We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05). Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death. Median follow-up was 3.01 (1.39–4.98) years. AT was identified in 1935 out of 2137 patients (90.54%). At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001). At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97–0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01–1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87–1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94–0.96), renal function (modification of diet in renal disease; P<0.05; HR=0.990; CI=0.98–0.99), sodium (P<0.05; HR=0.967; CI=0.94–0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06–1.89). Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09–1.10). Similar results were obtained for the secondary study end point.

Received April 2, 2013; accepted July 15, 2013.
From the Centro Cardiologico Monzino, IRCCS, Milano, Italy (P.A., G.C., F.V., E.B., C.F., E.S., M.G., V.M., A.A., P.P., M.C.); Department of Clinical Sciences and Community Health, Cardiovascular Section, Università di Milano, Milano, Italy (P.A., C.F.); Department of Respiratory and Critical Care Medicine, University of Washington, Seattle, WA (P.A.); Divisione di Cardiologia Riabilitativa, Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Veruno, Veruno, Italy (U.C., A.M.); Section of Cardiology, Department of Medicine, University of Verona, Verona, Italy (E.B., M.C., C.V.); Division of Cardiology, “S. Maugeri” Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy (R.L.G., D.S.); UOC Cardiologia Ospedale S. Spirito - Roma Lungotevere in Sassi 3, Roma, Italy (A.B.S., R.R.); Fondazione Gabriele Monasterio, CNR-Regione Toscana, Pisa, Italy (M.E., C.P.); Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy (M.M.); Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy (G.S., A.I.); Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Napoli, Italy (G.L.); Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Trastate, Dipartimento di Medicina e Riabilitazione Cardiorespiratoria Unità Operativa di Cardiologia Riabilitativa, Tradate, Italy (R.R.); Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, St. Camillo-Forlanini Hospital, Roma, Italy (F.R.); Department of Medical Sciences, Cardiology, IRCCS San Donato Hospital, University of Milan, San Donato Milanese, Milano, Italy (M.G.); Cardiologia Riabilitativa, Azienda Ospedali Riuniti, Ancona, Italy (R.B.); Department of Health Science, University of Milano Bicocca, Milano, Italy (G.P.); Department of Cardiology, S. Luca Hospital, Istituto Auxologico Italiano, Milano, Italy (G.P.); Dipartimento di Medicina Clinica e Molecolare, “Sapienza” Università degli Studi di Roma, Roma, Italy (D.M.); Centro Cardiovascolare, Azienda per i Servizi Sanitari n° I, Trieste, Italy (A.D.L.); Department of advanced biomedical sciences, Federico II University, Napoli, Italy (S.P.); Scuola Superiore S. Anna, Pisa, Italy (C.P.); and UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy (M.F.P.).
* A list of all MECKI Score Research Group is given in the Appendix.
Correspondence to Piergiuseppe Agostoni, MD, PhD, Centro Cardiologico Monzino, IRCCS, Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, via Parco, 4, 20138, Milano, Italy. E-mail piergiuseppe.agostoni@unimi.it
© 2013 American Heart Association, Inc.
Circ Heart Fail is available at http://circheartfailure.ahajournals.org
DOI: 10.1161/CIRCHEARTFAILURE.113.000471
Downloaded from http://circheartfailure.ahajournals.org/ by guest on January 20, 2016
T he anaerobic threshold (AT) concept is based on the principle that energy production shifts from an aerobic metabolism to a metabolism that combines both anaerobic and aerobic patterns during a progressively increasing workload exercise.1,2 According to the concept of threshold, the shift of metabolic pathway during incremental exercise must be more or less simultaneous among active muscular fibers. Therefore, the distribution of blood flow during exercise to and into muscles, the resistance to O₂ flow between capillaries and mitochondria, the type of muscular fibers, and their metabolic capability must be relatively homogeneous.3 This is not always the case in patients with heart failure (HF) who have an uneven distribution of blood flow to muscles and an uneven use of O₂, so that, for example, an important percentage of subjects with HF increase their capillary PO₂ toward the end of exercise.4–7 Inhomogeneity of blood flow distribution, of O₂ flow resistance, and of O₂ use should widen the time frame where anaerobiosis starts to develop among the muscular fibers, in few cases making the threshold indefinable. If this hypothesis is correct, then AT should be more frequently undetectable in patients with a more severe disease.8

Clinical Perspective on p 987

From a clinical point of view, the value of oxygen uptake (VO₂) at AT is used for grading the severity of HF or the effects of therapy, or to assess cardiovascular risk in case of surgery.9–18 and it has been proposed as an alternative to peak VO₂, being it independent of patients’ motivation, exercise protocol, and exercise duration.19 However, even in the presence of anaerobic metabolism, AT is not identified in a large number of patients with HF.8,20–22 It is unknown whether the finding of a reached but indeterminable AT has a clinical meaning.

The present study was therefore undertaken to assess the clinical and prognostic significance of AT detection in patients with systolic HF. To find it out, we used a multicenter HF database, generated and continuously updated by the metabolic exercise and cardiac kidney index (MECKI) score research group.23

Methods

Population

The study cohort consists of a population of patients with systolic HF recruited and prospectively followed up in 14 Italian HF centers (Appendix 2). At enrollment, patients were evaluated, and clinical history, laboratory, ECG, echocardiographic, and cardiopulmonary exercise test (CPET) data were collected. Study inclusion/exclusion criteria and patients’ follow-up were previously described.23 In brief, we evaluated patients with present or previous history of HF who had been in New York Heart Association functional class I to III, stable clinical conditions, and medication since ≥3 months before enrollment. Patients with comorbidities affecting exercise capacity or with exercise-induced angina or significant ECG alterations were excluded. Only patients who performed what they considered as a maximal effort were included in the original database. In the present analysis, however, to be sure that anaerobic metabolism was reached during exercise, we only evaluated patients who achieved a peak exercise respiratory quotient (RQ) >1.05.

Clinical laboratory and echocardiographic evaluations were recorded as previously described.21 In brief, we recorded anthropometric parameters, HF pathogenesis, hemoglobin (Hb), serum sodium (Na⁺), potassium (K⁺), and creatinine. We calculated glomerular filtration rate by means of the modification of diet in renal disease (MDRD) formula.24 Left ventricular volumes and ejection fraction (LVEF) were calculated by echocardiography.25

Cardiopulmonary Exercise Tests

CPET were performed using an electronically braked cycle-ergometer or a treadmill. For comparison with cycle-ergometer, treadmill peak VO₂ data were reduced by 10%.26 The exercise protocol was set to achieve peak exercise in 10 minutes.27 In the absence of clinical events, CPET was self-interrupted by the patients when they stated that they had reached a maximal effort. Expiratory gases and ventilation data were recorded and analyzed by breath by 2 CPET experts. AT was measured by V-slope analysis of VO₂ and VCO₂, and it was confirmed by ventilatory equivalents and end-tidal pressures of CO₂ and O₂.1,27 If AT was not detected or a significant disagreement on its value was reported by ≥2 experts, AT was considered as not identified. Exercise-induced periodic breathing was defined as a cyclic fluctuation of ventilation.28 Ventilatory efficiency (VE/VCO₂) slope was calculated as the linear relation slope between VE and VCO₂ from 1 minute after the beginning of loaded exercise up to the isocapnic buffering period.

Patient Grouping

Data were analyzed considering the entire population and after grouping patients according to peak VO₂ and MECKI score, a recently reported HF prognostic score that combines CPET, echocardiographic and laboratory parameters, namely peak VO₂ (%pred), VE/VCO₂, slope, LVEF, Na⁺, MDRD, and Hb.25 As previously done by Wasserman et al.,27 3 peak VO₂-based groups were defined: peak VO₂ < 12 mL/min per kilogram, between 12 and 16 and >16. As for MECKI score, patients were divided into tertiles. Finally, we grouped patients with identified AT according to their VO₂AT, and we compared them with patients without identified AT.

Patients’ Follow-Up

Patients’ follow-up was performed according to the local HF program in a theoretically endless fashion. Follow-up ended with the last clinical evaluation in the center where the patient had been recruited or with the patient’s death. If the patient did not show up at the scheduled follow-up visit, they or their family were called on the phone, and their visit was rescheduled at their desire. If the patient died outside the hospital where he was followed up, we obtained medical records of the event and the cause of death. Patients who died from noncardiovascular reasons were considered censored at the time of the event. The primary end point of the study was a composite of cardiovascular death, including stroke, and urgent cardiac transplant, and the secondary end point was all-cause death.

Data Management and Analysis

Details of data management were previously reported, including a data quality control management.23 In brief, a quality control was set up at Centro Cardiologico Monzino, where P.A. was the director of the center and responsible for data collection, while individual investigators were responsible for their own records. All investigators were experts on CPET and HF. Data collection was computerized. Quality data control included the control center staff as well as external
Statistical Analysis

Continuous variables were presented as means±SDs, and categorical variables were presented as frequencies and percentages. Anova or unpaired t test were used as appropriate for comparison between groups, and χ² test was used for comparing categorical variables. Skewed distributed variables were reported as median and interquartile range and compared by the Wilcoxon signed-rank test.

We used multivariable logistic regression model for evaluating, at baseline, the association between identifiable/unidentifiable AT and VO₂ and between identifiable/unidentifiable AT and MECKI score, adjusting the former for age. LVEF, MDRD, Na⁺, Hb, VE/VCO₂, and periodic breathing, and the latter for age and periodic breathing.

Potential predictors of mortality were identified by univariable Cox regression analysis. A multivariable Cox proportional hazard model was used for assessing the independent prognostic value of AT adjusted for the variables significant at the univariable analysis. When MECKI score was considered in multivariable analysis, parameters generating this score were excluded. Hazard ratios and 95% confidence intervals were calculated. Kaplan–Meier survival curves were implemented for AT, and survival curves were compared using log-rank test. A regression-based imputation analysis was used for missing data on Hb, Na⁺, and MDRD. Although there is a small difference between the percentages of missing data in the 2 groups of unidentiﬁed/identiﬁed AT, there is no relationship between AT and missing data, because of some reasons. First of all, we included AT together with age, sex, VO₂ peak (% of predicted), VE/VCO₂ slope, LVEF in the regression model. Second, a sensitivity analysis was performed to assess a model without the imputation approach, and the hazard ratio did not change, thus we can assume missing data as missing at random. The number of missing data for Hb was 289, and =120 for each variable for Na⁺ and MDRD. No data were missing for the other variables. Cox regression was also performed after grouping patients according to peak VO₂ and MECKI score. A P<0.05 value considered as statistically significant. Statistical analysis was performed using SAS 9.2 (SAS Institute, Inc, Cary, NC) or IBM SPSS 20.0 (SPSS-PC+ Inc, Chicago, IL).

Results

We obtained data from 3058 patients with HF who met the study inclusion/exclusion criteria. A total of 921 cases were excluded from further analysis because their peak VO₂ was ≤1.05 (Figure 1). The remaining 2137 patients performed CPET on a cycle-ergometer (2085 cases) or on a treadmill (52 cases). Mean follow-up was 3.4 years (range 1 day to 14 years). We observed 562 total deaths, 482 cardiovascular deaths, and 87 urgent cardiac transplants. At study enrollment, 78% of patients were treated with angiotensin I–converting enzyme inhibitors, 13% with angiotensin II receptor blockers, 80% with β-blockers, 79% with diuretics, 48% with antialdosteronic drugs, 47% with antiplatelets drugs, 31% with oral anticoagulants, 26% with digitals, and 25% with amiodarone. Moreover, 18% of patients had implantable cardioverter-defibrillator, and 8% of patients had a cardiac resynchronization therapy. Peak VO₂ was <12 mL/min per kilogram in 618 cases, between 12 and 16 in 798 cases, and >16 in 721 cases. Some of the most often recognized prognostic HF parameters of the entire population are reported in Table 1.

Table 1. Differences According to Anaerobic Threshold Identification in the Total Population

<table>
<thead>
<tr>
<th></th>
<th>Total Population (N=2137)</th>
<th>Identified AT (n=1935)</th>
<th>Unidentified AT (n=202)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>60±12</td>
<td>60±12</td>
<td>63±12</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (m/f)</td>
<td>1801/336</td>
<td>1649/286</td>
<td>152/50</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VE/VCO₂ slope</td>
<td>33.0±7.6</td>
<td>32.5±7.2</td>
<td>38.3±9.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VO₂ (% of predicted)</td>
<td>53.6±15.5</td>
<td>54.2±15.3</td>
<td>45.0±14.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hb, g/dL</td>
<td>13.5±1.5</td>
<td>13.5±1.5</td>
<td>13.2±1.6</td>
<td>0.006</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>31.0±9.0</td>
<td>31.3±9.0</td>
<td>29.3±9.4</td>
<td>0.001</td>
</tr>
<tr>
<td>MDRD, mL/min</td>
<td>68.9±21.6</td>
<td>69.3±21.7</td>
<td>35.0±21.7</td>
<td>0.012</td>
</tr>
<tr>
<td>Na⁺, mmol/L</td>
<td>139.4±3.1</td>
<td>139.4±3.2</td>
<td>139.7±3.2</td>
<td>0.298</td>
</tr>
<tr>
<td>PB, n (%)</td>
<td>399 (18.6)</td>
<td>314 (16.0)</td>
<td>85 (42)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MECKI score*</td>
<td>0.103 (0.03–0.14)</td>
<td>0.059 (0.03–0.13)</td>
<td>0.13 (0.05–0.23)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Exercise duration, min</td>
<td>8.12±2.87</td>
<td>8.31±2.84</td>
<td>6.23±2.51</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are mean±SD and median (interquartile ranges) for continuous variables or number (%) of subjects for categorical variables. P values were calculated by Student t test or Wilcoxon Rank-Sum Test or by χ² when appropriate. AT indicates anaerobic threshold; Hb, hemoglobin; LVEF, left ventricular ejection fraction; MDRD, modification of diet in renal disease; MECKI, metabolic exercise and cardiac and kidney indexes; Na⁺, sodium; PB, periodic breathing during exercise; VE/VCO₂, ventilatory efficiency; and VO₂, oxygen uptake.

*Identifies the probability of cardiovascular death or urgent cardiac transplant within 2 y.
Patients with peak VO₂ <12 mL/min per kilogram or in the highest MECKI tertile (≥0.104) had a more severe HF, were older, mainly male, with higher VE/VO₂ slope, lower Hb concentration, and lower LVEF and renal function (Tables 2 and 3). AT was not identified in 202 cases (9.45%), belonging in 110 (18%), 67 (8%), and 25 (3%) cases to group <12, 12 to 16, and >16 mL/min per kilogram, respectively (P<0.001 and 33 (17%), 50 (26%), and 112 (57%) cases to the first, second, and third tertiles of MECKI score, respectively. Moreover, peak VO₂, or MECKI score, and impossibility to detect AT resulted significantly associated with univariable and multivariable logistic regression model (P<0.001), adjusting the latter for age, LVEF, MDRD, Na+, Hb, VE/VO₂ and periodic breathing (peak VO₂), or for age and periodic breathing (MECKI score).

Characteristics of patients with HF according to the presence or absence of AT identification are reported in Table 1. Patients with HF in whom AT was reached, but not detected, were older and more often female, had most often periodic breathing, higher VE/VO₂ and MECKI score, and lower peak VO₂, Hb, LVEF, and kidney function. In each peak VO₂−based group, the presence of an identified/unidentified AT was associated with significant differences in measured parameters: VE/VO₂ slope, peak VO₂, presence of periodic breathing, and MECKI score in peak VO₂ <12 mL/min per kilogram patients, VE/VO₂ slope, sex, presence of periodic breathing in peak VO₂ between 12 and 16 mL/min per kilogram patients; presence of periodic breathing in peak VO₂ >16 mL/min per kilogram patients (Tables 2 and 3), all suggestive of a more severe disease in those with unidentifed AT. Similarly, when grouping patients according to MECKI score tertiles, unidentified AT was associated to MECKI values suggestive of poorer prognosis (Tables 2 and 3).

The impossibility of identifying AT was associated to a significantly worse prognosis at Kaplan–Meier evaluation in the entire population (Figure 2) and, when grouping patients, only in the group with lower peak VO₂ (<12 mL/min per kilogram) patients or in patients with the highest tertile of the MECKI score (≥0.104; Figure 3). Conversely, in patients with less severe exercise impairment, as those with peak VO₂ between 12 and 16 mL/min per kilogram or with peak VO₂ >16 mL/min per kilogram, or in patients with less severe HF, as those with middle or lowest MECKI score tertiles, the impossibility of identifying AT was only associated with a not significant trend toward a worse prognosis at Kaplan–Meier evaluation, likely because of the lower incidence of AT nonidentification and to the lower amount of events in these patients (Figure 3). However, when formally tested, the interaction between AT identification and peak VO₂ or MECKI groups was not significant. Patients with HF with identified AT (n=1935) were grouped in tertiles according to VO₂ value at AT: AT ≤8.5 mL/min per kilogram (n=644), between 8.5 and 11.0 (n=640), and ≥11.0 (n=650), and those with lower VO₂ values had a worse prognosis. However, the patients with unidentified AT had the worst survival considering both end points of the study (Figure 4). Multivariable analysis was performed considering the variables that were linked to prognosis at univariable analysis (Table 4). Peak VO₂ (%), VE/VO₂ slope, Hb, Na+, MDRD, LVEF, and the
impossibility of identifying AT were independently related to prognosis, regardless of the study end point considered (Table 5). Notably, the impossibility of identifying AT maintained a significant prognostic role. A similar result was obtained including the MECKI score value in the multivariable analysis, instead of using the single variables by which the score is derived (peak VO2 [%], VE/VCO2 slope, Hb, Na+, MDRD, LVEF; Table 5). We also performed a VO2 stratified Cox regression according to the 3 above-reported peak VO2 classes, comparing patients with HF with unidentified versus identified AT. Hazard ratios were 1.77 (1.24–2.53), 1.15 (0.67–1.96), and 1.10 (0.35–3.48) for peak VO2 <12 mL/min per kilogram, 12 to 16 mL/min per kilogram, and >16 mL/min per kilogram, respectively. After adjusting for MECKI score, hazard ratios were 1.57 (1.09–2.27), 1.17 (0.69–2.00), and 0.85 (0.26–2.72), respectively.

Discussion

This study shows that, in patients with HF who reached anaerobic metabolism as defined by a peak exercise RQ >1.05 during an incremental exercise, AT was not identified by standard
methods in 10% of cases. This percentage was significantly higher in most patients with severe HF. The impossibility of identifying AT was associated to a worse prognosis. Notably, this impossibility maintained its negative prognostic role in HF even at a multivariable analysis, which included several HF prognostic parameters.

Defining an effort as maximal for a given individual is a matter of debate. Indeed, in the absence of significant clinical

Figure 3. Survival rate of patients with most severe heart failure, according to oxygen uptake (VO2; A).
Figure 3 (Continued), or metabolic exercise and cardiac and kidney index (MECKI) score (B). Kaplan–Meier curves, according to anaerobic threshold identification for the primary end point (death+urgent cardiac transplant, left) and for the secondary end point (all-cause death, right), stratify only in patients with lower peak VO2 or higher MECKI score. Green line=identified AT group; Blue line=not identified AT group.
events, CPET is self-interrupted by patients when they feel that they have reached a maximal effort, regardless of the encouragement to continue by the supervising medical staff. In HF, a RQ ratio >1.05 is considered as an indication of a significant effort by the patient.30 Several prognostic studies in HF have considered CPET data as relevant,13,14,18,23,31 including VO2 at AT.9–17,31 In the present study, we confirmed this finding. However, although anaerobic metabolism had been reached, AT was not identified in ≈10% of cases, making it difficult to allocate these patients in a specific HF or surgical risk category. Indeed, the evidence of RQ >1.05 at peak exercise of a ramp protocol exercise test implies that the anaerobic metabolism has been used to produce ATP regardless of AT identification.32 In a previous study, we showed that the impossibility of identifying AT was associated to CPET parameters suggestive of poor exercise performance.8 However, the presence of a true maximal effort was not mandatory in that study, so that an indeterminable AT was associated, at least in some cases, with a poor effort by the patients and a submaximal exercise.8 Conversely, in the present study, we excluded =30% of patients from the analysis because RQ was ≤1.05, although they reported a maximal effort. An indeterminable AT in patients with HF who performed a maximal or nearly maximal effort and reached anaerobic metabolism was inversely related to peak VO2, and to HF prognosis as assessed by the MECKI score. The majority of patients with unidentified AT had peak VO2 <12 mL/min per kilogram and a MECKI score ≥0.104. Accordingly, these patients belong to a high-risk category of HF patients, as suggested by peak VO2 and MECKI score as well as by several other parameters (Tables 2 and 3).23

The finding that the impossibility of identifying AT in patients with HF who reached anaerobic metabolism during exercise has a prognostic role is a novel observation. Most importantly, patients with an unidentified AT had a poor prognosis, worse than patients with low VO2 at AT (≤8.5 mL/min per kilogram). Our finding extends to patients with HF who likely reached anaerobic metabolism unlike that in the previous observations by Katz et al22 and Opasich et al,32 who showed that peak VO2 maintains its prognostic role even in patients with severe HF in whom AT was not detected. Indeed, conversely from Katz et al22 and Opasich et al,32 we have excluded subjects who, for a variety of reasons, did not perform a metabolic maximal or nearly maximal effort, and we showed a prognostic role of an unidentified AT independent of several prognostic variables including peak VO2. Notably, the lack of AT identification has a demonstrated negative prognostic capacity only in patients with most severe HF. Indeed, the number of cases of AT nonidentification and of events observed in our population with less severe HF (Figure 3) was relatively small and insufficient for interaction analysis. Some technical aspects may be the reason for an undetectable AT, including a test too short to collect enough data points and a relevant hyperventilation at the beginning of exercise. The former may be because of the selection of a too demanding ramp protocol. Indeed, although the average exercise duration in patients with undetectable AT was shorter (6.23±2.51 minutes), it was long enough to allow the collection of an adequate amount of data points for AT detection. We previously showed that workload, but not VO2, at AT was lower in short tests (5 minutes) than in longer tests (10 and 15 minutes), but AT was identified or not identified independently of test duration.19 Also psychogenic hyperventilation may make AT identification difficult. However, in case of hyperventilation, CO2 storages are significantly reduced, so that RQ declines during exercise, and an RQ >1.05 is rarely observed at peak exercise. Several physiological mechanisms may also explain why AT is not identifiable: an uneven intramuscle and intermuscle distribution of blood flow during exercise, an uneven O2 flow resistance between capillary bed and mitochondria, and the presence of muscular fibers with uneven O2 extraction/utilization capability are the most likely.1–7 In sum, the time frame during which anaerobiosis develops in the different muscle fibers in a ramp protocol exercise becomes wide, so that a threshold shared by the majority of muscle fibers does not exist. It is therefore conceivable that the identification of AT most often lacks in
patients with severe HF, who most frequently have the above-described physiological impairments. In the present study, we showed that an unidentified AT was related to several parameters suggestive of a worse prognosis, including the presence of exercise-induced periodic breathing.14,28 Indeed, periodic breathing may, per se, make AT identification difficult, particularly when it lasts throughout the exercise. This is the case in a minority of patients with exercise-induced periodic breathing,33 but this information was unfortunately not available for the present data set of patients. Moreover, in 58% of cases with an unidentified AT, exercise-induced periodic breathing was not observed.

Few study limitations should be acknowledged. First, we admit that, by applying \( \leq 1.05 \) as peak exercise RQ cutoff value, we likely excluded some patients with HF who had a true maximal test. Second, because the follow-up was quite long, treatment strategies were required to be upgraded in many patients, including implantable cardioverter-defibrillator implantation and cardiac resynchronization therapy implementation, which might have, per se, influenced the prognosis. Third, several parameters known to be related to HF prognosis

Table 4. Heart Failure Prognosis (Univariable Analysis)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cardiovascular Death Transplant Hazard Ratio</th>
<th>95% Hazard Ratio Confidence Limits</th>
<th>( P )</th>
<th>All-Cause Death Hazard Ratio</th>
<th>95% Hazard Ratio Confidence Limits</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>1.01</td>
<td>1.002 1.019</td>
<td>0.0212</td>
<td>1.01</td>
<td>1.002 1.019</td>
<td>0.0123</td>
</tr>
<tr>
<td>Sex</td>
<td>1.133</td>
<td>0.835 1.484</td>
<td>0.4659</td>
<td>1.167</td>
<td>0.886 1.535</td>
<td>0.2714</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>0.993</td>
<td>0.922 0.945</td>
<td>&lt;0.001</td>
<td>0.941</td>
<td>0.931 0.952</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MDRD, mL/min</td>
<td>0.983</td>
<td>0.978 0.989</td>
<td>&lt;0.001</td>
<td>0.986</td>
<td>0.981 0.99</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Na+, mmol/L</td>
<td>0.959</td>
<td>0.929 0.99</td>
<td>0.009</td>
<td>0.963</td>
<td>0.935 0.992</td>
<td>0.014</td>
</tr>
<tr>
<td>Hb, mg/dL</td>
<td>0.857</td>
<td>0.801 0.917</td>
<td>&lt;0.001</td>
<td>0.843</td>
<td>0.791 0.898</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VE/VCO₂ slope</td>
<td>1.057</td>
<td>1.046 1.068</td>
<td>&lt;0.001</td>
<td>1.055</td>
<td>1.045 1.066</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VO₂ ( % of predicted)</td>
<td>0.958</td>
<td>0.95 0.965</td>
<td>&lt;0.001</td>
<td>0.959</td>
<td>0.952 0.966</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PB</td>
<td>1.314</td>
<td>1.033 1.67</td>
<td>0.0259</td>
<td>1.311</td>
<td>1.046 1.644</td>
<td>0.0189</td>
</tr>
<tr>
<td>MECKI score*</td>
<td>1.56</td>
<td>1.505 1.68</td>
<td>&lt;0.001</td>
<td>1.558</td>
<td>1.477 1.643</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AT nonidentification</td>
<td>1.949</td>
<td>1.479 2.567</td>
<td>&lt;0.0001</td>
<td>1.894</td>
<td>1.455 2.466</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

AT indicates anaerobic threshold; Hb, hemoglobin; LVEF, left ventricular ejection fraction; MDRD, modification of diet in renal disease; MECKI, metabolic exercise and cardiac and kidney indexes; Na⁺, sodium; PB, periodic breathing; VE/VCO₂, ventilatory efficiency; and VO₂, oxygen uptake.

*Hazard ratio expressed for each 0.1 U of MECKI score increase.

Table 5. Heart Failure Prognosis (Multivariable Analysis) With and Without MECKI Score

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cardiovascular Death Transplant Hazard Ratio</th>
<th>95% Hazard Ratio Confidence Limits</th>
<th>( P )</th>
<th>All-Cause Death Hazard Ratio</th>
<th>95% Hazard Ratio Confidence Limits</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>1.002</td>
<td>0.99 1.012</td>
<td>0.7224</td>
<td>1.004</td>
<td>0.99 1.014</td>
<td>0.4657</td>
</tr>
<tr>
<td>VO₂ ( % of predicted)</td>
<td>0.977</td>
<td>0.97 0.986</td>
<td>&lt;0.001</td>
<td>0.977</td>
<td>0.97 0.986</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>VE/VCO₂ slope</td>
<td>1.02</td>
<td>1.01 1.033</td>
<td>&lt;0.01</td>
<td>1.019</td>
<td>1.01 1.032</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Hb, mg/dL</td>
<td>0.931</td>
<td>0.87 1.00</td>
<td>0.0498</td>
<td>0.909</td>
<td>0.85 0.973</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Na⁺, mmol/L</td>
<td>0.967</td>
<td>0.94 0.998</td>
<td>0.0358</td>
<td>0.968</td>
<td>0.94 0.998</td>
<td>0.0338</td>
</tr>
<tr>
<td>MDRD, mL/min</td>
<td>0.99</td>
<td>0.98 0.995</td>
<td>&lt;0.001</td>
<td>0.992</td>
<td>0.99 0.998</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>0.948</td>
<td>0.94 0.961</td>
<td>&lt;0.001</td>
<td>0.955</td>
<td>0.94 0.967</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PB</td>
<td>1.032</td>
<td>0.8 1.325</td>
<td>0.8056</td>
<td>1.044</td>
<td>0.83 1.322</td>
<td>0.7194</td>
</tr>
<tr>
<td>AT nonidentification</td>
<td>1.414</td>
<td>1.06 1.893</td>
<td>0.0202</td>
<td>1.39</td>
<td>1.05 1.838</td>
<td>0.0207</td>
</tr>
</tbody>
</table>

With MECKI score

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cardiovascular Death Transplant Hazard Ratio</th>
<th>95% Hazard Ratio Confidence Limits</th>
<th>( P )</th>
<th>All-Cause Death Hazard Ratio</th>
<th>95% Hazard Ratio Confidence Limits</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>1.004</td>
<td>0.99 1.013</td>
<td>0.4452</td>
<td>1.005</td>
<td>0.99 1.014</td>
<td>0.2747</td>
</tr>
<tr>
<td>PB</td>
<td>1.059</td>
<td>0.825 1.359</td>
<td>0.6531</td>
<td>1.069</td>
<td>0.845 1.353</td>
<td>0.5778</td>
</tr>
<tr>
<td>MECKI score*</td>
<td>1.568</td>
<td>1.482 1.659</td>
<td>&lt;0.001</td>
<td>1.535</td>
<td>1.453 1.622</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AT nonidentification</td>
<td>1.459</td>
<td>1.096 1.943</td>
<td>&lt;0.01</td>
<td>1.446</td>
<td>1.099 1.901</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

AT indicates anaerobic threshold; Hb, hemoglobin; LVEF, left ventricular ejection fraction; MDRD, modification of diet in renal disease; Na⁺, sodium; PB, periodic breathing; VE/VCO₂, ventilatory efficiency; and VO₂, oxygen uptake.

*Hazard ratio expressed for each 0.1 U of MECKI score increase.
were not considered, such as intraventricular delay and BNP (brain natriuretic peptide) or NT-proBNP (N-terminal-proBNP) value. Fourth, we have not measured blood lactates during exercise, so that we did not evaluate whether the presence of an undetectable AT was associated to a lower or higher amount of exercise-induced lactic acid production. Finally, we have no information on reproducibility of undetection of AT.

In conclusion, we observed for the first time that the absence of an identifiable AT has an independent prognostic role in HF, considering several parameters related to HF prognosis at multivariable analysis either as isolated parameters or as combined in the MECKI score. This is attributable to the strong physiological meaning of an undetectable AT. Therefore, the VO₂ value at AT is clinically relevant in HF if anaerobic metabolism is reached, but also the finding of the impossibility of identifying AT should be carefully considered. Consequently, patients with HF with an undetectable AT should be considered at high risk.9–18

Appendix 1

Other members of the MECKI score research group are the following: Centro Cardiologico Monzino, IRCCS, Milano: Erica Bertella, Stefania Farina; Cardiologia Riabilitativa, Istituto Auxologico Italiano: Gabriella Malfatto; Cardiologia SUN, Ospedale Monaldi Napoli: Giuseppe Pacileo, Teo Roselli, Andrea Buono, Raffaele Calabrò; S. Maugeri Foundation, IRCCS, Cassano Murge: Andrea Passantino, Daniela Santoro, Saba Campana, Domenica Caputo; S. Maugeri Foundation, Tradate: Donatella Bertipaglia, Ospedali Riuniti, Trieste: Marco Confalonieri, S. Maugeri Foundation, Cassano Murge; 216 at Fondazione G. Monasterio, Pisa; 121 at S. Maugeri Foundation, Tradate; 41 at Lancisi Hospital, Cassano Murge; 216 at Fondazione G. Monasterio, Milano: Erica Bertella, Cattadori G, Schmid JP, Kilikowski C, Kleemann T, Kilikowski A, Bangert M, Schneider S, Schwarz A, Senges J. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death. Circulation. 2002;106:3079–3084.

Appendix 2

Recruitment of patients: A total of 924 patients were recruited and followed at Centro Cardiologico Monzino, Milan; 332 at S. Maugeri Foundation, Cassano Murge; 216 at Fondazione G. Monasterio, Pisa; 121 at S. Maugeri Foundation, Tradate; 41 at Lanzis Hospital, Ancona; 77 at Monaldi Hospital, Naples; 260 at S. Spirito Hospital, Rome; 22 at S. Luca Hospital, Milan; 59 at S. Paolo Hospital, Milan; 219 at Ospedali Civili, Brescia; 171 at Ospedali Riuniti, Trieste; 356 at S. Maugeri Foundation, Veruno; 64 at S. Camillo Hospital, Rome; and 196 at Ospedale Civile Maggiore, Verona.

Disclosures

None.

References


We observed for the first time that the absence of an identified anaerobic threshold has an independent prognostic role in heart failure, considering several parameters related to heart failure prognosis at multivariable analysis either as isolated parameters or as combined in the metabolic exercise, cardiac and kidney index score (MECKI score). This is attributable to the strong physiological meaning of an unidentifiable anaerobic threshold. Indeed, several physiological mechanisms may explain why anaerobic threshold is not identifiable: an uneven intramuscle and intermuscle distribution of blood flow during exercise, an uneven O₂ flow resistance between capillary bed and mitochondria, and the presence of muscular fibers with uneven O₂ extraction/utilization capability are the most likely. In sum, the time frame during which anaerobiosis develops in the different muscle fibers in a ramp protocol exercise becomes wide, so that a threshold shared by the majority of muscle fibers does not exist. For a clinical point of view, the present study is useful because it enables an understanding of information previously considered noninformative as relevant prognostic information, which we need to consider when evaluating a cardiopulmonary exercise test in patients with heart failure.
Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure
Piergiuseppe Agostoni, Ugo Corrà, Gaia Cattadori, Fabrizio Veglia, Elisa Battaia, Rocco La Gioia, Angela B. Scardovi, Michele Emdin, Marco Metra, Gianfranco Sinagra, Giuseppe Limongelli, Rosa Raimondo, Federica Re, Marco Guazzi, Romualdo Belardinelli, Gianfranco Parati, Damiano Magri, Cesare Fiorentini, Mariantonietta Cicoira, Elisabetta Salvioni, Marta Giovannardi, Alessandro Mezzani, Domenico Scrutinio, Andrea Di Lenarda, Valentina Mantegazza, Roberto Ricci, Anna Apostolo, AnnaMaria Iorio, Stefania Paolillo, Pietro Palermo, Mauro Contini, Corrado Vassanelli, Claudio Passino and Massimo F. Piepoli
on behalf of the MECKI Score Research Group*

Circ Heart Fail. 2013;6:977-987; originally published online July 23, 2013;
doi: 10.1161/CIRCHEARTFAILURE.113.000471
Circulation: Heart Failure is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/6/5/977

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Heart Failure can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Heart Failure is online at:
http://circheartfailure.ahajournals.org//subscriptions/